Cellvizio's microscopic living images are improving the way physicians see the body and diagnose -
and treat - its diseases.
In this issue of the Cellvizio News,
we talk to three top gastroentero- logists about Cellvizio's potential to impact treatment.
As top medical centers start using the system commercially next year, we will be ramping efforts to help sites
enroll patients in two international clinical studies, which are intended to confirm earlier results in
Barrett's Esophagus and biliary cancer detection. A steady stream of new clinical evidence will be presented at key medical meetings throughout 2009.
We believe these efforts will help underscore the impact
that Cellvizio can have on therapeutic patient management, improved patient care and efficiency within the hospital.
Sacha Loiseau
PhD, President, CEO and Founder
 |
| January 23-25, 2009 |
|
Cedars Sinai
16th International Symposium on Pancreatic & Biliary Endoscopy,
Los Angeles, California |
| |
| February 6-7 2009 |
|
11th International Symposium on Diagnostic and Therapeutic Endoscopy, 2009,
Düsseldorf, Germany |
| |
For more detailed information on Cellvizio's involvement
at the conferences,
please click here
|
|
 |
|
Going deep : Cellvizio Used to Visualize Furthest Reaches of Brain
Institut Pasteur researchers have demonstrated microsco- pic, real-time imaging of the deepest regions of the brain in a freely moving mouse,
using it to analyse brains expressing Green Fluorescent Protein, the protein at the base of this year's Nobel Prize in Chemistry.
"This advance should have profound impact on the field of neurological research,"
said Uwe Maskos, DPhil, a Lab Chief at Institut Pasteur.
"Gaining understanding of neurological activity throughout the brain is vital to understanding normal brain function and the kinds of alterations
that lead to neurological disorders."
Dr. Maskos presented his findings at the Society for Neuroscience 38th Annual 2008 Meeting in Washington, D.C. in November.
French Lab Uses Cellvizio to Explore Cellular Processes Inside Living Animals
Researchers at the National Institute for Agronomic Research's (INRA),
Research Center of Jouy-en-Josas (CRJ) in France have acquired a FCM1000 system with Cellvizio®
technology to advance their studies of living animals biological processes.
Dr. Kaïs H. Al-Gubory of the Development and Reproduction Biology unit is the first physiologist to use and vali- date Cellvizio®
as a way to monitor dynamic cellular pro- cess such
as programmed cell death in the natural physiological environment of the living animals
and to
monitor tissue architectu- re and cell morphology in organs of transgenic rabbits expressing the enhanced GFP (eGFP) gene.
Using Cellvizio technology will also allow the research unit
to save more animals and reduce the time and expense associated with manipulation procedures required for tra- ditional histopathology analy- sis.
|
|
|
|
|
|
New International Study Launches To Confirm Cellvizo's Role in Reducing Esophageal Cancer
|
The first patients have been treated in a new international study designed to confirm Cellvizio's positive
results in accurately detecting pre-can- cerous Barrett's Esophagus tissue
|
The goal is to confirm that viewing esophageal tissue at the cellular level with the Cellvizio probe increases
the ability to identify and immediately remove abnormal tissue without as many biopsies.
Columbia-Presbyterian Medical Center in New York City, the Veterans Affairs Hospital in Kansas City, Mayo Clinic in Jacksonville,
Florida and Klinikum rechts der Isar in Munich, Germany plan to enroll more than 100 patients in the study,
known as DONT BIOPCE
(Detection Of Neoplastic Tissue
in Barrett's Esophagus with In vivO
Probe-based Confocal Endomicroscopy).
Details can be found on www.clinicaltrials.gov
(ClinicalTrials.gov Identifier: NCT00795184).
New Published Data Underscore How Microscopic Imaging with Cellvizio®
Improves Biopsy Targeting in Barrett's Esophagus
New published data add to the growing body of clinical evidence demonstrating how
Cellvizio helps physicians locate Barrett's Esophagus tissue that has the highest chance of progressing into cancer.
The study, led by Heiko Pohl, MD, MPH of the Dartmouth-Hitchcock Medical Center, appears in the December issue of GUT.
"Using images from this tiny microscope, we were able to show that a physician who is trained to use the Cellvizio
device almost always identifies the normal tissue accurately," Dr. Pohl said.
Click here to see the study.
Clinical cases : Much Ado about Mayo
In November, Cellvizio was active at the 17th Annual Mayo GI & Hepatology Advances case studies held in Orlando,
Florida.
Dr. Ananya Das, Mayo Scottsdale, performed a live Barrett's procedure and discovered dysplasia with
Cellvizio and subsequently performed targeted EMR.
Drs. Herbert Wolfsen and Anna Buchner, both of Mayo Jacksonville,
also performed a live Barrett's case and their colleague, Dr. Michael Wallace, captivated the audience in one of
the program's Hands-On-Sessions using video to clearly depict image interpretation performed by
Cellvizio. Dr. Wallace followed his demonstration up with a Meet-The-Professor luncheon on Imaging Techniques.
|
|
 |
|
Top Endoscopy Suppliers to Sell Cellvizio across Europe
Dedicated teams will now be selling Cellvizio systems to gastroenterologists in five major European markets.
Diagmed Healthcare Limited will distribute the system throughout the United Kingdom, while Grupo Cofares'
EndoTécnica unit and Endoscopiki S.A. will distribute Cellvizio in Spain and Greece, respectively.
RMS Endoscopy will sell to the Belgian market as well as in Luxembourg.
Mauna Kea Technologies continues to sell Cellvizio directly in France, Germany and Switzerland.
|
|
|
|
Three Top Physicians Discuss
How Cellvizio is Not Only Helping Change
the Way They Detect GI and Biliary Disease, But How They Treat It
|
David L. Carr-Locke, M.D., F.R.C.P., F.A.S.G.E.
Director, The Endoscopy Institute, Brigham & Women's Hospital, Boston
|
Dr. Carr-Locke, Past-President of the International Hepato-Pancreato-Biliary Association and
Past-President of the American Society for Gastrointestinal Endoscopy, demonstrated the system in two
live cases at the Boston International Live Endoscopy Course (BILEC) in September.
"Whenever I see a new technology that can tell us something we couldn't achieve before, the natural thing for me to think about is,
'How does this determine treatment?'
Just making a diagnosis is very good, but it doesn't make a huge difference for the patient if you end up doing the same thing you did before.
If it changes the way you treat a disease, then of course that has a huge impact and I think that's what this could do for us."
Click here for the full interview.
|
Charles J. Lightdale, M. D.
Professor of Clinical Medicine, Division of Digestive and Liver Diseases at Columbia-Presbyterian Medical Center, New York
|
"It does give us the potential to do more accurate sampling. Targeted biopsies will be much more accurate in detecting dysplasia. Also, when we identify the abnormal living tissue,
it allows us to do an immediate therapy like an endoscopic mucosal resection."
Click here for the full interview.
|
Marc Giovannini, M.D.
Head of Endoscopic Unit, Paoli-Calmettes Institut, Marseilles, FRANCE
|
"[EUS with the fine needle aspiration] was quite equivalent in terms of therapeutic
and decision impact; and I hope Cellvizio will have the same impact in the coming years."
Click here for the full interview.
Click here to see all the testimonials.
|
|
|
|
